Limits...
Comparative activity of carbapenem testing (the COMPACT study) in Turkey.

Leblebicioglu H, Cakir N, Celen M, Kurt H, Baris H, Laeuffer J, Turkish COMPACT Study Gro - BMC Infect. Dis. (2012)

Bottom Line: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008.In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.

View Article: PubMed Central - HTML - PubMed

Affiliation: Ondokuzmayis University, Kurupelit Kampüsü, Samsun, Turkey. hakanomu@omu.edu.tr

ABSTRACT

Background: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.

Methods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.

Results: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.

Conclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.

Show MeSH

Related in: MedlinePlus

Cumulative% minimum inhibitory concentration (MIC) distributions against Acinetobacter baumannii (N = 53).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298475&req=5

Figure 3: Cumulative% minimum inhibitory concentration (MIC) distributions against Acinetobacter baumannii (N = 53).

Mentions: For Enterobacteriaceae, doripenem and meropenem were equally active (MIC90 0.12 mg/L) and at least four-fold more active than imipenem (MIC90 0.5 mg/L; Figure 2). At MIC 0.5 mg/L (the FDA breakpoint for doripenem against Enterobacteriaceae), 97.5% were susceptible to doripenem, 93.75% to imipenem, and 97.5% to meropenem. At MIC ≤ 4 mg/L (the 2009 CLSI breakpoint for imipenem and meropenem against Enterobacteriaceae), 98.75% were susceptible to doripenem, 98.33% to imipenem, and 98.75% to meropenem. At MIC ≤ 1 mg/L (the new breakpoint for imipenem and meropenem, as well as doripenem, against Enterobacteriaceae established by CLSI in June 2010), 97.92% were susceptible to doripenem, 96.67% to imipenem and 97.92% to meropenem. Also at MIC ≤ 1 mg/L, 100% of E. coli and 94.1% of K. pneumoniae were susceptible to each of the three carbapenems. The MIC90 for all three carbapenems against other Gram-negative isolates, including A. baumannii (Figure 3), was ≥ 64 mg/L.


Comparative activity of carbapenem testing (the COMPACT study) in Turkey.

Leblebicioglu H, Cakir N, Celen M, Kurt H, Baris H, Laeuffer J, Turkish COMPACT Study Gro - BMC Infect. Dis. (2012)

Cumulative% minimum inhibitory concentration (MIC) distributions against Acinetobacter baumannii (N = 53).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298475&req=5

Figure 3: Cumulative% minimum inhibitory concentration (MIC) distributions against Acinetobacter baumannii (N = 53).
Mentions: For Enterobacteriaceae, doripenem and meropenem were equally active (MIC90 0.12 mg/L) and at least four-fold more active than imipenem (MIC90 0.5 mg/L; Figure 2). At MIC 0.5 mg/L (the FDA breakpoint for doripenem against Enterobacteriaceae), 97.5% were susceptible to doripenem, 93.75% to imipenem, and 97.5% to meropenem. At MIC ≤ 4 mg/L (the 2009 CLSI breakpoint for imipenem and meropenem against Enterobacteriaceae), 98.75% were susceptible to doripenem, 98.33% to imipenem, and 98.75% to meropenem. At MIC ≤ 1 mg/L (the new breakpoint for imipenem and meropenem, as well as doripenem, against Enterobacteriaceae established by CLSI in June 2010), 97.92% were susceptible to doripenem, 96.67% to imipenem and 97.92% to meropenem. Also at MIC ≤ 1 mg/L, 100% of E. coli and 94.1% of K. pneumoniae were susceptible to each of the three carbapenems. The MIC90 for all three carbapenems against other Gram-negative isolates, including A. baumannii (Figure 3), was ≥ 64 mg/L.

Bottom Line: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008.In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.

View Article: PubMed Central - HTML - PubMed

Affiliation: Ondokuzmayis University, Kurupelit Kampüsü, Samsun, Turkey. hakanomu@omu.edu.tr

ABSTRACT

Background: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.

Methods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.

Results: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.

Conclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.

Show MeSH
Related in: MedlinePlus